secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134758
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q1 Royalty Receipts +14% to $705M; FY2024 guidance reaffirmed
----------------------------------------------------------------------------

- Portfolio Receipts of $717M, down 37% from $1,131M YoY due to $475M Biohaven milestone in Q1 2023.
- Royalty Receipts grew 14% to $705M, led by Evrysdi, Trelegy, and the cystic fibrosis franchise.
- Full-year 2024 Portfolio Receipts guidance reaffirmed at $2.6B–$2.7B, with Royalty Receipts growth of 5%–9%.
- Announced ~$525M acquisition of royalties on Sanofi’s frexalimab (Phase 3 multiple sclerosis); $5.9B total liquidity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/0001193125-24-134758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524134758/d834416d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer